http://www.zgazyw.com/Article/20240514142956-7920_1.html Web28 nov. 2024 · 袁芃教授展示了KEYNOTE-119的研究结果,免疫治疗的效果与PD-L1的表达有关,PD-L1表达越高疗效越好。. 但目前从PD-L1表达的结果来看,还未达到优于化疗的水平。. 不过这是一个初期研究成果,免疫治疗还在不断的开发新的适应症,为患者的治疗带来 …
ESMO热评丨李曼教授:晚期三阳性乳腺癌「免化疗」再添OS证据
WebMonarcHER研究是第一个去化疗联合靶向治疗方案与化疗联合靶向治疗方案头对头比较,且取得较好PFS结果的研究。 本届ESMO大会上,MonarcHER研究OS结果公布,【肿瘤 … Web10 nov. 2024 · Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice … grammatical signals and expressions examples
李俊杰教授:monarchE研究亚洲人群结果公布,早期乳腺癌强化内 …
Web2024年ESMO大会将于2024年9月9日~13日在巴黎召开,来自欧洲肿瘤研究所的乳腺癌专家Paolo Tarantino博士在Twitter上推荐了值得关注的乳腺癌研究TOP10 ... +曲妥珠单抗相比,阿贝西利+氟维司群+曲妥珠单抗具有显著的PFS获益。本次会议上将汇报monarcHER研究 … Web1 sep. 2024 · Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC). Web1 dec. 2024 · Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Abemaciclib when combined with ET is the first CDK4/6 inhibitor to demonstrate a significant improvement in IDFS in patients with HR+, HER2- node-positive EBC at high risk of early recurrence. grammatical parts of a letter